DK1913157T3 - EGFR og KRAS mutationer til forudsigelse af patientrespons for EGFR inhibitorbehandling - Google Patents

EGFR og KRAS mutationer til forudsigelse af patientrespons for EGFR inhibitorbehandling

Info

Publication number
DK1913157T3
DK1913157T3 DK06773201.6T DK06773201T DK1913157T3 DK 1913157 T3 DK1913157 T3 DK 1913157T3 DK 06773201 T DK06773201 T DK 06773201T DK 1913157 T3 DK1913157 T3 DK 1913157T3
Authority
DK
Denmark
Prior art keywords
egfr
patient response
inhibitor therapy
kras mutations
predicting patient
Prior art date
Application number
DK06773201.6T
Other languages
English (en)
Other versions
DK1913157T4 (da
Inventor
Kenneth J Hillan
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36999856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1913157(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1913157T3 publication Critical patent/DK1913157T3/da
Publication of DK1913157T4 publication Critical patent/DK1913157T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK06773201.6T 2005-06-28 2006-06-13 EGFR- og KRAS-mutationer til forudsigelse af patientrespons på EGFR-hæmmerbehandling. DK1913157T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69517405P 2005-06-28 2005-06-28
PCT/US2006/023230 WO2007001868A1 (en) 2005-06-28 2006-06-13 Egfr and kras mutations

Publications (2)

Publication Number Publication Date
DK1913157T3 true DK1913157T3 (da) 2013-03-11
DK1913157T4 DK1913157T4 (da) 2017-01-23

Family

ID=36999856

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06773201.6T DK1913157T4 (da) 2005-06-28 2006-06-13 EGFR- og KRAS-mutationer til forudsigelse af patientrespons på EGFR-hæmmerbehandling.

Country Status (9)

Country Link
US (4) US20090202989A1 (da)
EP (1) EP1913157B2 (da)
JP (2) JP2008546421A (da)
CA (1) CA2612183C (da)
DK (1) DK1913157T4 (da)
ES (1) ES2398709T5 (da)
PL (1) PL1913157T5 (da)
SI (1) SI1913157T2 (da)
WO (1) WO2007001868A1 (da)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2082090C (en) 1991-11-05 2004-04-27 Jack Fagan Improved occluder for repair of cardiac and vascular defects
DE69229539T2 (de) 1991-11-05 2000-02-17 Children's Medical Center Corp., Boston Okklusionsvorrichtung zur Reparatur von Herz- und Gefäss-Defekten
ES2133382T3 (es) 1992-01-21 1999-09-16 Univ Minnesota Dispositivo para el cierre de defectos septales.
BRPI0314042B8 (pt) 2002-09-06 2021-05-25 Calando Pharmaceuticals Inc polímeros à base de ciclodextrina para o fornecimento de agentes terapêuticos ligados a eles por covalência
EP1766068A4 (en) 2004-06-04 2010-03-03 Genentech Inc EGFR Mutations
MX2007009963A (es) 2005-02-24 2007-09-26 Amgen Inc Mutaciones del receptor del factor de crecimiento epidermico.
US7635570B2 (en) 2005-04-01 2009-12-22 Salvatore Siena Epidermal growth factor receptor gene copy number
PL1913157T5 (pl) * 2005-06-28 2017-09-29 Genentech Inc Mutacje EGFR i KRAS do prognozowania reakcji pacjenta na leczenie inhibitorem EGFR
ATE520979T1 (de) * 2005-08-24 2011-09-15 Bristol Myers Squibb Co Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
US7906342B2 (en) 2006-03-31 2011-03-15 Biodesix, Inc. Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
US7858390B2 (en) * 2006-03-31 2010-12-28 Biodesix, Inc. Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CN103424541B (zh) 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
US12366585B2 (en) 2006-05-18 2025-07-22 Caris Mpi, Inc. Molecular profiling of tumors
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
ES2426814T3 (es) * 2007-03-13 2013-10-25 Amgen Inc. Mutaciones de K-ras y B-raf y terapia con anticuerpos anti-EGFr
AR065687A1 (es) * 2007-03-13 2009-06-24 Amgen Inc Metodo para determinar la presencia o no de una mutacion k-ras y terapia con anticuerpos anti-egfr
CN101795703B (zh) 2007-06-27 2015-05-06 里兰斯坦福初级大学理事会 肽酪氨酸酶抑制剂及其应用
CN101795702B (zh) 2007-06-27 2014-08-06 里兰斯坦福初级大学理事会 寡肽酪氨酸酶抑制剂及其应用
EP2245199B1 (en) * 2008-02-01 2013-11-13 The General Hospital Corporation Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
US8273534B2 (en) 2008-05-14 2012-09-25 Genomic Health, Inc. Predictors of patient response to treatment with EGF receptor inhibitors
US8583380B2 (en) 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
NZ592241A (en) * 2008-09-15 2012-11-30 Herlev Hospital Ykl-40 as a marker for gastrointestinal cancers
GB2463401B (en) 2008-11-12 2014-01-29 Caris Life Sciences Luxembourg Holdings S A R L Characterizing prostate disorders by analysis of microvesicles
WO2011109440A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings Biomarkers for theranostics
IL313131A (en) * 2009-02-11 2024-07-01 Caris Mpi Inc Molecular characterization of tumors
US20130143747A1 (en) * 2011-12-05 2013-06-06 Myriad Genetics, Incorporated Methods of detecting cancer
IN2012DN01403A (da) * 2009-08-24 2015-06-05 Genentech Inc
WO2011031877A1 (en) 2009-09-09 2011-03-17 The General Hospital Corporation Use of microvesicles in analyzing nucleic acid profiles
EP2475989A4 (en) * 2009-09-09 2013-02-27 Gen Hospital Corp USE OF MICROVESICLES IN THE ANALYSIS OF KRAS MUTATIONS
US20110059081A1 (en) * 2009-09-09 2011-03-10 Quintiles Transnational Corp. Methods and compositions for the treatment of receptor tyrosine kinase mediated diseases or disorders
US20110160159A1 (en) * 2009-09-15 2011-06-30 John Ryan Treatment of cancer
EP2327793A1 (en) 2009-11-25 2011-06-01 Universität Zu Köln Pyrosequencing method for predicting the response of a patient towards anti cancer treatment
US20110207736A1 (en) 2009-12-23 2011-08-25 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
CA2783656A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2542699A4 (en) * 2010-03-03 2013-10-02 Targeted Molecular Diagnostics Llc METHODS FOR DETERMINING REACTIVITY TO A MEDICINE BASED ON DETERMINATION OF RAS MUTATION AND / OR RAS AMPLIFICATION
CA2783665A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2542692B1 (en) 2010-03-04 2016-08-24 Carpén, Olli Method for selecting patients for treatment with an egfr inhibitor
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
CN102234683B (zh) * 2010-04-23 2013-07-17 广州益善生物技术有限公司 一种egfr基因突变检测液相芯片
US20130095473A1 (en) * 2010-06-14 2013-04-18 Qiagen Gmbh Method for determination of target cells or tissue for extraction of biomolecules from fixed biological samples
US20140045915A1 (en) 2010-08-31 2014-02-13 The General Hospital Corporation Cancer-related biological materials in microvesicles
RU2565550C2 (ru) 2010-09-24 2015-10-20 Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити Прямой захват, амплификация и секвенирование днк-мишени с использованием иммобилизированных праймеров
CN103080314B (zh) * 2010-09-30 2016-04-13 Lsip基金运营联合公司 显性突变基因表达抑制剂
JP6219721B2 (ja) 2010-11-10 2017-10-25 エキソソーム ダイアグノスティックス インコーポレイテッド 核酸含有粒子の単離および該粒子からの核酸の抽出のための方法
GB2506760B (en) * 2011-01-14 2015-07-22 Genefirst Ltd Allele specific primers for EGFR exon 21 specific mutations
WO2012102829A1 (en) 2011-01-28 2012-08-02 Biodesix, Inc. Predictive test for selection of metastatic breast cancer patients for hormonal and combination therapy
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
EP2715347A4 (en) * 2011-05-26 2014-12-03 Univ Brandeis EVIDENCE OF SEQUENCE VARIANTS OF THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) GENE
WO2013058868A2 (en) * 2011-10-18 2013-04-25 Exact Sciences Corporation Multiplexed kras mutation detection assay
CN104039328B (zh) 2011-11-11 2018-10-09 米伦纽姆医药公司 对蛋白酶体抑制剂的反应的生物标记
EP2823306A4 (en) * 2012-03-09 2015-11-11 Caris Life Sciences Switzerland Holdings Gmbh BIOMARKER COMPOSITIONS AND METHODS
WO2014028221A1 (en) * 2012-07-31 2014-02-20 Crown Bioscience, Inc. Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-egfr drug
DK2884979T3 (da) 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
CA2886397A1 (en) * 2012-09-26 2014-04-03 Insight Genetics, Inc. Methods and compositions relating to next generation sequencing for genetic testing in alk related cancers
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
US20140199405A1 (en) * 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
US10328062B2 (en) 2014-04-04 2019-06-25 Amgen, Inc. Biomarkers and use of MET inhibitor for treatment of cancer
US10835948B2 (en) 2014-07-09 2020-11-17 The Boeing Company Adjustable retaining structure for a cradle fixture
AU2016350701B2 (en) 2015-11-02 2021-08-19 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
CN106834484A (zh) * 2017-02-27 2017-06-13 宁夏海诚电化信息科技有限公司 一种直肠癌体外检测方法
CN114286676A (zh) * 2019-08-22 2022-04-05 密歇根大学董事会 治疗kras相关癌症的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683203A (en) * 1984-04-14 1987-07-28 Redco N.V. Immobilized enzymes, processes for preparing same, and use thereof
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5981725A (en) * 1989-09-08 1999-11-09 The Johns Hopkins Univiersity Structural alterations of the EGF receptor gene in human tumors
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US5869245A (en) 1996-06-05 1999-02-09 Fox Chase Cancer Center Mismatch endonuclease and its use in identifying mutations in targeted polynucleotide strands
EP1163365A4 (en) * 1999-02-25 2002-11-20 Auckland Uniservices Ltd DIAGNOSIS AND THERAPY OF EARLY OVARY FAILURE
EP1170011A1 (en) * 2000-07-06 2002-01-09 Boehringer Ingelheim International GmbH Novel use of inhibitors of the epidermal growth factor receptor
EP1636380A2 (en) * 2003-05-30 2006-03-22 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
CN101501211A (zh) * 2004-03-31 2009-08-05 综合医院公司 测定癌症对表皮生长因子受体靶向性治疗反应性的方法
EP1766068A4 (en) * 2004-06-04 2010-03-03 Genentech Inc EGFR Mutations
PL1913157T5 (pl) * 2005-06-28 2017-09-29 Genentech Inc Mutacje EGFR i KRAS do prognozowania reakcji pacjenta na leczenie inhibitorem EGFR

Also Published As

Publication number Publication date
SI1913157T1 (sl) 2013-02-28
JP2013099330A (ja) 2013-05-23
PL1913157T3 (da) 2013-04-30
ES2398709T5 (es) 2017-04-18
JP2008546421A (ja) 2008-12-25
US20090202989A1 (en) 2009-08-13
EP1913157B2 (en) 2016-10-26
EP1913157B1 (en) 2012-11-28
EP1913157A1 (en) 2008-04-23
US20150197814A1 (en) 2015-07-16
CA2612183C (en) 2015-08-11
CA2612183A1 (en) 2007-01-04
US20110081651A1 (en) 2011-04-07
DK1913157T4 (da) 2017-01-23
ES2398709T3 (es) 2013-03-21
WO2007001868A1 (en) 2007-01-04
US20130203788A1 (en) 2013-08-08
SI1913157T2 (sl) 2017-02-28
JP5827935B2 (ja) 2015-12-02
PL1913157T5 (pl) 2017-09-29

Similar Documents

Publication Publication Date Title
DK1913157T3 (da) EGFR og KRAS mutationer til forudsigelse af patientrespons for EGFR inhibitorbehandling
LTC1761540I2 (lt) Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės-delta inhibitoriai
DK2099796T3 (da) Aza-indolyl-forbindelser og fremgangsmåder for anvendelse
NO20085030L (no) Pyrrolopyrimidinforbindelser og deres anvendelser
IL250734A0 (en) Transdermal therapeutic system
DK1871738T3 (da) N-alkylcarbonylaminosyreester- og N-alkylcarbonylaminolactonforbindelser og deres anvendelse
DK1888033T3 (da) Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme
ATE423121T1 (de) Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren
DK1962895T3 (da) TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST
DK1940839T3 (da) Pyridopyrimidione Inhibitors of P13Ka
IS8597A (is) Samsetningar rísedrónats og aðferðir við notkun þess
DK3424932T3 (da) Bronophthalider til terapeutisk anvendelse
DK1924577T3 (da) Substituerede benzimidazoler og fremgangsmåder til fremstilling
DK2152748T3 (da) Anti-Notch1-NRR-antistoffer og fremgangsmåder til anvendelse deraf
EP1901635A4 (en) SUPPORT FOR PATIENT
CY2014012I2 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
DK2578685T3 (da) Rna indeholende modificerede nukleosider og fremgangsmåder til anvendelse deraf
DK1720866T3 (da) Fremgangsmåde
DK1954140T3 (da) Glycerollevulinatketaler og deres anvendelse
DK1948180T3 (da) Kombinationsbehandling af cancer omfattende EGFR/HER2 inhibitorer
DK1706112T3 (da) Fremgangsmåder til at behandle en inflammatorisk-beslægtet sygdom
DK1917246T3 (da) Benzoquinazolinderivater og deres anvendelse til behandling af knoglesygdomme
DK1830838T3 (da) Sammensætninger og fremgangsmåder til behandling af neoplastiske sygdomme
DK2001556T3 (da) Thioninium-forbindelser og anvendelse deraf
NO20054709D0 (no) Sammenfoyningssystem og anvendelse av dette